

Supplementary Table 3. Summary of AVA Status by Infusion-Related Reactions and Hypersensitivity reactions

Outcome, yes/no Overall AVA status	Induction phase		Maintenance phase	
	Vedolizumab IV (n = 27)	Placebo (n = 10)	Vedolizumab SC (n = 10)	Vedolizumab IV (n = 2)
Infusion-related reactions				
Yes				
No.	0	0	0	0
AVA negative	0	0	0	0
AVA positive	0	0	0	0
No				
No.	27	10	10	2
AVA negative	25 (92.6)	7 (70)	9 (90)	2 (100)
AVA positive	2 (7.4)	3 (30)	1 (10)	0
Hypersensitivity reactions				
Yes				
No.	2	0	6	1
AVA negative	2 (100)	0	6 (100)	1 (100)
AVA positive	0	0	0	0
No				
No.	25	10	4	1
AVA negative	23 (92)	7 (70)	3 (75)	1 (100)
AVA positive	2 (8)	3 (30)	1 (25)	0

Values are presented as number (%).

AVA, anti-vedolizumab antibody; IV, intravenous; SC, subcutaneous.